{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 40,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "Includes specific clinical trial safety metrics (AEs, SAEs, CTCAE grades).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/13",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.38,
        "x": 0.58,
        "y": 0.21
      },
      "kind": "list",
      "text": "No treatment-related deaths; Few treatment-related SAEs; Very few related AEs leading to treatment discontinuation; No clinically meaningful on-target toxicity; Differentiated profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f93d540-875f-4cdb-bd5c-758ff73b2cde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Interim data- Data cut-off of Oct 17, 2022. CTCAE definitions and footnotes.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f52b103-5006-4cd6-bfaf-31ea52cf41f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.43,
        "x": 0.11,
        "y": 0.56
      },
      "kind": "table",
      "text": "Specific adverse event grades for Constipation, Peripheral Neuropathy, and Diarrhea",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92892bb3-d756-47f3-9c8d-15f2cfc0417b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "table",
      "text": "Adverse events table comparing BA3011 and BA3011 + Nivolumab",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f846353-2e2e-4ea8-b351-c102a1b3fab4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Continued promising safety and tolerability profile in Sarcoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ad774b0-7ad6-44aa-bfa1-e3974d2494cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Phase 2 at the RP2D 1.8 mg/kg Q2W",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e4300c1-233b-4b7f-8c2f-74938e14766b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "ccfe9b49-4707-4b8b-b9bb-6ed766d33b47",
      "evidence": "Presents clinical trial safety data in a structured table and bulleted summary format.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 15,
      "from": 9,
      "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck presents the potential market opportunity for BioAtla's CABs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732",
      "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs",
      "position": 1,
      "objective": "What are the key results and milestones for BioAtla's CABs?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}